The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-12
DOI
10.3389/fonc.2021.646979
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-line therapies in advanced biliary tract cancers
- (2020) Sri Harsha Tella et al. LANCET ONCOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
- (2020) Lu Xie et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
- (2020) Avani Athauda et al. CANCER TREATMENT REVIEWS
- The Tumor Microenvironment in Cholangiocarcinoma Progression
- (2020) Luca Fabris et al. HEPATOLOGY
- Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
- (2020) Yubin Hu et al. Cancer Management and Research
- Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
- (2020) Jianzhen Lin et al. Hepatobiliary Surgery and Nutrition
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
- (2019) Dongxu Wang et al. Journal of Hematology & Oncology
- Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials
- (2019) Lijun Liang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
- (2019) Joseph W Franses et al. Lancet Gastroenterology & Hepatology
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma
- (2019) Sylvie Job et al. HEPATOLOGY
- Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
- (2018) Alex B. Blair et al. CURRENT PROBLEMS IN CANCER
- Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
- (2018) Lesley J. Scott DRUGS
- Burden of Liver Diseases in the World
- (2018) Sumeet K. Asrani et al. JOURNAL OF HEPATOLOGY
- The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study
- (2018) Liu Zhen et al. Journal of Cancer
- PD-L1 expression in extrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. HISTOPATHOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
- (2014) John Bridgewater et al. JOURNAL OF HEPATOLOGY
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
- (2013) D Sia et al. ONCOGENE
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started